Cellular Therapies
Human Platelet Lysate (HPL)
HPL is frequently requested from Blood Centers either as outdated platelet concentrates or more elaborate products. A review written by members of the WP is available here.
We currently work on the questions of dosing, use of fresh vs outdated platelets, storage conditions and quality control sources or platelets. We encourage exchange between groups and support contacts.
More literature regarding Human Platelet Lysate by Members of the Group is available here:
- Current methods to manufacture human platelet lysates for cell therapy and tissue engineering: possible trends in product safety and standardizationISBT Science Series
- A double-virally-inactivated (Intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells Transfusion
- Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cellsNew Biotechnology
- The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways Tissue Engineering and Regenerative Medicine
- International Forum on GMP-grade human platelet lysate for cell propagation: summaryVox Sanguinis
- Multifaceted regenerative lives of ‘expired’ plateletsISBT Science Series
- Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansionNew Technology
- Removal of Transmissible Spongiform Encephalopathy Prion from Large Volumes of Cell Culture Media Supplemented with Fetal Bovine Serum by Using Hollow Fiber Anion-Exchange Membrane Chromatography Plos One
- Human platelet lysate current standards and future developmentsTransfusion
- Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's diseaseBiomaterials
- The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTHJournal of Thrombosis and Haemostasis
- Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansionCytotherapy
A summary paper of the Workshop held in Zurich in March 2018 by our ISBT Working Party on „Human Platelet Lysate – Current Standards and Future Developments“ can be found here:
Autologous Serum Eye drops
Literature co-authored by Members of the Working Group is available here:
- Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believingTransfusion and Apheresis Science
- Reflections on Dry eye Syndrome Treatment: Therapeutic Role of Blood Products Frontiers in Medicine
- Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye SyndromePlos One
The group of Denese Marks in the Australian Red Cross Blood Service, Sydney has published a review which is recommended to read.
Pieter van der Meer and colleagues from Sanquin Blood Supply, The Netherlands also published a review in 2016 on SED.
Extracellular vesicles
Extracellular vesicles are secreted by almost all cell types. These small carriers are found in all body fluids and are considered to be key components in cell-cell communication. A recent review with contribution form the Working Party can be found here:
Unproven Cellular Therapies
We consider this as an important topic that transfusionsists should be aware of and have an attitude to. The International Society of Cellular Therapies (ISCT) has published a manuscript containing recommendations which we support (DOI: 10.1016/j.jcyt.2015.10.007).
Biobanking for Therapeutic Purposes
The WP is currently working on defining approaches towards Biobanking, and collecting references for currenty regulatory standards.